Reset filter
Keywords
Clinical Trial ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

130 Search results.
Relevance Rating New first Old first

Sunitinib in HIV with Cancer NCT00890747 AMC-061 - Off Study Summary Form (F50)

- 6/20/17 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: Off-Study Summary
AMC-061 Off Study Summary Form (F50) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Survival Follow-Up

- 10/13/20 - 1 form, 2 itemgroups, 5 items, 1 language
Itemgroups: Date of visit, Assessment Date, follow-up, Continuance of life
Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Cycle 1 - Week 4

- 10/13/20 - 1 form, 9 itemgroups, 163 items, 1 language
Itemgroups: Date of visit, Assessment Date, Neurologic Examination, Neurologic Symptoms, Associated with, Neoplasms, Laboratory Procedures, Central Laboratory; Laboratory Procedures, Local, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Hematology finding, Central Laboratory, Data, Vital signs, Continuation status, Study
Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases

Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073 - Conclusion

- 10/13/20 - 1 form, 4 itemgroups, 9 items, 1 language
Itemgroups: Date of visit, Assessment Date, Cessation of life, Pregnancy, Information, Conclusion, Clinical Research
Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases

Death Form (F04) Brain and Central Nervous System Tumors (NCT00890747)

- 1/8/15 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Death Information
AMC-061 Death Form (F04) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy NCT00890747 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=71988CF7-F80D-68F0-E040-BB89AD4358A1

Brain and Central Nervous System Tumors NCT00890747 Demographic - AMC-061 Demographic Form (DEM) - 2978032v1.0 - AMC-061 Demographic Form (DEM)

- 9/17/21 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: Demographics
AMC-061 Demographic Form (DEM) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7C6E3CDA-FFD3-B993-E040-BB89AD432712

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314 - Therapy and toxicity cycle 10-13

- 9/20/21 - 16 forms, 16 itemgroups, 68 items, 1 language
Itemgroups: Therapy cycle 10-13, Therapy after cycle, Propranolol, Propranolol therapy deviation, Celecoxib, Celecoxib deviation, Cyclophosphamide, Cyclophosphamide deviation, Vinblastine, Vinblastine deviation, Toxicity overview, Toxicity, Hospitalization, Comments, Transfusion, Footer module
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln

Therapy and toxicity cycle > 13

16 itemgroups 68 items

Therapy and toxicity cycle 1-3

16 itemgroups 68 items

Therapy and toxicity cycle 4-6

16 itemgroups 68 items

Therapy and toxicity cycle 7-9

16 itemgroups 68 items

Baseline

13 itemgroups 77 items

Reference

12 itemgroups 111 items

NCT01041950 Hydrocephalus - Treatment Group

- 11/15/17 - 1 form, 10 itemgroups, 47 items, 1 language
Itemgroups: Lumbar Liquor Drainage, Attempt to disconnect LD, Liquor Drainage: Amount, Bleeding Complication, Overdrainage LD, Cerebrospinal Fluid Finding, Change of Drainage, Shunt, Discharge, Clinical Outcome
NCT01041950 Lumbar Drainage for Communicating Hydrocephalus After Intraventricular Hemorrhage: a Randomised, Controlled Trial(LUCAS-IVH: LUmbar CAtheter for Severe IntraVentricular Hemorrhage) Copyright-Holder: Prim. Priv.-Doz. Dr. med. Dimitre Staykov Krankenhaus Eisenstadt Prof. Dr. med. Dr. Hagen B. Huttner Universitätsklinikum Erlangen Treatment Group

NCT01041950 Hydrocephalus - Control Group

- 11/15/17 - 1 form, 11 itemgroups, 44 items, 1 language
Itemgroups: EVD Liquordrainage, Attempt to disconnect EVD, Liquor Drainage: Amount, Comment, Bleeding Complication, Overdrainage LD, Cerebrospinal Fluid Finding, Change of Drainage, Shunt, Discharge, Clinical Outcome
NCT01041950 Lumbar Drainage for Communicating Hydrocephalus After Intraventricular Hemorrhage: a Randomised, Controlled Trial(LUCAS-IVH: LUmbar CAtheter for Severe IntraVentricular Hemorrhage) Copyright-Holder: Prim. Priv.-Doz. Dr. med. Dimitre Staykov Krankenhaus Eisenstadt Prof. Dr. med. Dr. Hagen B. Huttner Universitätsklinikum Erlangen Control Group

NCT01041950 Hydrocephalus - Eligibility Criteria

- 11/10/17 - 1 form, 10 itemgroups, 34 items, 1 language
Itemgroups: General Information, Demographics, Diagnostic CCT, Admission, Medical History, Insertion of External Ventricular Drainage, Intraventricular Fibrinolysis, CT Progression of Cerebral Hemorrhage, EVD Disconnection, Safety Issue
NCT01041950 Lumbar Drainage for Communicating Hydrocephalus After Intraventricular Hemorrhage: a Randomised, Controlled Trial(LUCAS-IVH: LUmbar CAtheter for Severe IntraVentricular Hemorrhage) Copyright-Holder: Prim. Priv.-Doz. Dr. med. Dimitre Staykov Krankenhaus Eisenstadt Prof. Dr. med. Dr. Hagen B. Huttner Universitätsklinikum Erlangen Eligibility Criteria

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial